von Willebrand disease: advances in pathogenetic understanding, diagnosis, and therapyEpidemiological investigation of the prevalence of von Willebrand’s diseaseInconsistency of association between type 1 von Willebrand disease phenotype and genotype in families identified in an epidemiological investigationThe prevalence of symptomatic von Willebrand disease in primary care practiceThe mutational spectrum of type 1 von Willebrand disease: results from a Canadian cohort studyvon Willebrand factor propeptide and the phenotypic classification of von Willebrand diseaseClinical and laboratory variability in a cohort of patients diagnosed with type 1 VWD in the United StatesVWF propeptide and ratios between VWF, VWF propeptide, and FVIII in the characterization of type 1 von Willebrand diseasevon Willebrand disease (VWD): evidence-based diagnosis and management guidelines, the National Heart, Lung, and Blood Institute (NHLBI) Expert Panel report (USA)Principles of care for the diagnosis and treatment of von Willebrand diseaseThe diagnosis and management of von Willebrand disease: a United Kingdom Haemophilia Centre Doctors Organization guideline approved by the British Committee for Standards in HaematologyAssociation of Hemophilia Clinic Directors of CanadaGenetic linkage and association analysis in type 1 von Willebrand disease: results from the Canadian type 1 VWD studyNovel insights into the clinical phenotype and pathophysiology underlying low VWF levelsUsefulness of patient interview in bleeding disordersBleeding/bruising symptomatology in children with and without bleeding disordersVon Willebrand disease type 1: a diagnosis in search of a diseaseBleeding scores for the diagnosis of von Willebrand diseaseISTH/SSC joint VWF and Perinatal/Pediatric Hemostasis Subcommittees Working GroupISTH/SSC bleeding assessment tool: a standardized questionnaire and a proposal for a new bleeding score for inherited bleeding disordersGeneration and validation of the Condensed MCMDM-1VWD Bleeding Questionnaire for von Willebrand diseaseNormal range of bleeding scores for the ISTH-BAT: adult and pediatric data from the merging projectSignificant gynecological bleeding in women with low von Willebrand factor levelsThe bleeding score predicts clinical outcomes and replacement therapy in adults with von Willebrand diseaseThe ISTH Bleeding Assessment Tool and the risk of future bleedingAmount of H antigen expressed on circulating von Willebrand factor is modified by ABO blood group genotype and is a major determinant of plasma von Willebrand factor antigen levelsThe relationship between ABO histo-blood group, factor VIII and von Willebrand factorEstrogens and surgery in women with von Willebrand’s diseaseThe effect of 17 beta-oestradiol on variables of coagulation and fibrinolysis in postmenopausal women with type 2 diabetes mellitusChanges in von Willebrand factor and factor VIII levels during the menstrual cycleDiurnal variation of von Willebrand factor in plasma: the Bispebjerg study of diurnal variationsMedicines & Healthcare products Regulatory Agency, UKEfficacy and safety of oral tranexamic acid in total knee arthroplasty: a systematic review and meta-analysisTranexamic acid for treatment of primary postpartum hemorrhage after vaginal delivery: a systematic review and meta-analysis of randomized controlled trialsIntravenous tranexamic acid use in revision total joint arthroplasty: a meta-analysisVasopressin-induced von Willebrand factor secretion from endothelial cells involves V2 receptors and cAMPDesmopressin: List of nationally authorised productsIntravenous and subcutaneous administration of desmopressin (DDAVP) to hemophiliacs: pharmacokinetics and factor VIII responsesDesmopressin responsiveness at a capped dose of 15 μg in type 1 von Willebrand disease and mild hemophilia AResponse to low-dose desmopressin by a subcutaneous route in children with type 1 von Willebrand diseaseIntranasal and intravenous administration of desmopressin: effect on F VIII/vWF, pharmacokinetics and reproducibilityBiologic response to desmopressin in patients with severe type 1 and type 2 von Willebrand disease: results of a multicenter European studyPhenotype and genotype of a cohort of families historically diagnosed with type 1 von Willebrand disease in the European study, Molecular and Clinical Markers for the Diagnosis and Management of Type 1 von Willebrand Disease (MCMDM-1VWD)Response to desmopressin is influenced by the genotype and phenotype in type 1 von Willebrand disease (VWD): results from the European Study MCMDM-1VWDReduced von Willebrand factor survival in type Vicenza von Willebrand diseaseOtolaryngologic surgery in children with von Willebrand diseaseManagement of children with inherited mild bleeding disorders undergoing adenotonsillar proceduresThe diagnosis of von Willebrand disease: a guideline from the UK Haemophilia Centre Doctors’ OrganizationPatterns of development of tachyphylaxis in patients with haemophilia and von Willebrand disease after repeated doses of desmopressin (DDAVP)Hyponatremia after desmopressin (DDAVP) use in pediatric patients with bleeding disorders undergoing surgeriesPostpartum von Willebrand factor levels in women with and without von Willebrand disease and implications for prophylaxisManagement of inherited bleeding disorders in pregnancy: Green-top Guideline No.